Key result
Vascular endothelial growth factor inhibitors are associated with the development of aortic dissection, highlighting the need for blood pressure monitoring and early diagnosis in treated patients.
Why the study?
Aortic dissection is an adverse reaction to vascular endothelial growth factor inhibitors with acute onset, rapid progression, and high fatality, but literature lacks clear population-level evidence.
Does VEGFI therapy induce aortic dissection in patients with tumors?
Does VEGFI therapy induce aortic dissection in patients with tumors?
Answers are grounded in this paper and cite their sources.
Vascular endothelial growth factor inhibitors are associated with a risk of aortic dissection, highlighting the need for rigorous blood pressure monitoring and prompt evaluation of severe pain in these patients.
Vascular endothelial growth factor (VEGF) contributes to angiogenesis and vasculogenesis. The occurrence and progression of tumors are accompanied by angiogenesis. Vascular endothelial growth factor inhibitors (VEGFI) have been used in anti-tumor treatment. However, aortic dissection (AD) is one of the VEGFI-associated adverse reactions with cute onset, rapid progression, and high case fatality rate. We collected case reports of VEGFI related to aortic dissection in PubMed and CNKI (China National Knowledge Infrastructure) from inception to 28 April 2022. Seventeen case reports were selected. The medication included sunitinib, sorafenib, pazopanib, axitinib, apatinib, anlotinib, bevacizumab, and ramucirumab. This review discusses the pathology, risk factors, diagnosis, and treatment of AD. Vascular endothelial growth factor inhibitors are related to aortic dissection. Although current literature lacks clear statistical evidence on the population, we offer points to encourage further confirmation of the best methods of care for these patients.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2023) conducted a review in Aortic dissection associated with vascular endothelial growth factor inhibitors (n=17). Vascular endothelial growth factor inhibitors (VEGFI) was evaluated. Vascular endothelial growth factor inhibitors are associated with the development of aortic dissection, highlighting the need for blood pressure monitoring and early diagnosis in treated patients.
Synapse has enriched 10 related papers. Consider them for comparative context: